# Anitocabtagene autoleucel PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/anitocabtagene-autoleucel

> The PDUFA target action date for anitocabtagene autoleucel, sponsored by GILEAD SCIENCES, INC. (GILD), is December 23, 2026, for relapsed or refractory multiple myeloma. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the anitocabtagene autoleucel PDUFA date?

The PDUFA target action date for anitocabtagene autoleucel, sponsored by GILEAD SCIENCES, INC. (GILD), is December 23, 2026, for relapsed or refractory multiple myeloma. Status: scheduled. Press release filed with the SEC (EX-99): "•Announced that the Biologics License Application for anito-cel in 4L+ R/R MM has been accepted by FDA, with a PDUFA target action date of December 23, 2026." Last confirmed October 30, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/anitocabtagene-autoleucel)

Source: Press release filed with the SEC (EX-99), accession 0000882095-26-000022, https://www.sec.gov/Archives/edgar/data/882095/000088209526000022/exhibit991earningspressrel.htm (retrieved 2026-11-12). Last confirmed 2026-10-30. Cite: https://sec-api.dev/pdufa/anitocabtagene-autoleucel#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | anitocabtagene autoleucel |
| Codes |  |
| Sponsor | GILEAD SCIENCES, INC. (GILD) https://sec-api.dev/companies/gild/catalysts |
| Indications | [relapsed or refractory multiple myeloma](https://sec-api.dev/indications/relapsed-or-refractory-multiple-myeloma), [Multiple Myeloma](https://sec-api.dev/indications/multiple-myeloma) |
| Modality | cell_therapy |
| FDA designations | none disclosed |

## Timeline

### May 7, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2026-05-07, last confirmed 2026-05-07.
- Press release filed with the SEC (EX-99) (accession 0000882095-26-000022): "•Announced that the Biologics License Application for anito-cel in 4L+ R/R MM has been accepted by FDA, with a PDUFA target action date of December 23, 2026." https://www.sec.gov/Archives/edgar/data/882095/000088209526000022/exhibit991earningspressrel.htm

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05396885 (Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Kite, A Gilead Company." https://clinicaltrials.gov/study/NCT05396885

### Dec 2026 to Mar 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05396885 (Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Kite, A Gilead Company." https://clinicaltrials.gov/study/NCT05396885

### December 23, 2026: PDUFA date

- Status: scheduled. Date confidence: exact. Stage: 1. Indication: relapsed or refractory multiple myeloma.
- First seen 2026-02-23, last confirmed 2026-10-30.
- Press release filed with the SEC (EX-99) (accession 0000882095-26-000022): "•Announced that the Biologics License Application for anito-cel in 4L+ R/R MM has been accepted by FDA, with a PDUFA target action date of December 23, 2026." https://www.sec.gov/Archives/edgar/data/882095/000088209526000022/exhibit991earningspressrel.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-018314): "The BLA for anito-cel as a fourth-line treatment for patients with relapsed or refractory multiple myeloma is supported by results from the Phase 1 study (NCT04155749) and the pivotal Phase 2 iMMagine1 study (NCT05396885) and has been accepted by the U.S. Food and Drug Administration with an anticipated Prescription Drug User Fee Act (PDUFA) action date of December 23, 2026." https://www.sec.gov/Archives/edgar/data/882095/000110465926018314/tm267044d1_ex99-1.htm
- SEC Form 10-Q (accession 0000882095-26-000039): "•Announced that the Biologics License Application for anito-cel in 4L+ R/R MM has been accepted by FDA, with a PDUFA target action date of December 23, 2026." https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/gild-20260930.htm
- SEC Form 10-Q (accession 0000882095-26-000031): "•Announced that the Biologics License Application for anito-cel in 4L+ R/R MM has been accepted by FDA, with a PDUFA target action date of December 23, 2026." https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/gild-20260630.htm
- SEC Form 10-Q (accession 0000882095-26-000024): "•Announced that the Biologics License Application for anito-cel in 4L+ R/R MM has been accepted by FDA, with a PDUFA target action date of December 23, 2026." https://www.sec.gov/Archives/edgar/data/882095/000088209526000024/gild-20260331.htm

### July 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06413498 (A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Kite, A Gilead Company." https://clinicaltrials.gov/study/NCT06413498

### Jul to Oct 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06413498 (A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Kite, A Gilead Company." https://clinicaltrials.gov/study/NCT06413498

## Same indication

- [Arlocabtagene autoleucel](https://sec-api.dev/pdufa/arlocabtagene-autoleucel) (BMY)
- [BB2121](https://sec-api.dev/pdufa/bb2121) (BMY)
- [Belantamab mafodotin](https://sec-api.dev/pdufa/belantamab-mafodotin) (GSK)
- [Cemsidomide](https://sec-api.dev/pdufa/cemsidomide) (CCCC)
- [Cilta-cel](https://sec-api.dev/pdufa/cilta-cel) (JNJ)
- [DARZALEX (daratumumab)](https://sec-api.dev/pdufa/daratumumab) (JNJ)
- [Empliciti (elotuzumab)](https://sec-api.dev/pdufa/elotuzumab) (BMY)
- [Elrexfio (elranatamab)](https://sec-api.dev/pdufa/elranatamab) (PFE)
- [Etentamig](https://sec-api.dev/pdufa/etentamig) (ABBV)
- [Zenbexus (iberdomide hydrochloride)](https://sec-api.dev/pdufa/iberdomide) (BMY)
- [ABECMA (idecabtagene vicleucel)](https://sec-api.dev/pdufa/idecabtagene-vicleucel) (BMY)
- [Igi, 10%](https://sec-api.dev/pdufa/igi-10) (TAK)
- [JNJ-79635322](https://sec-api.dev/pdufa/jnj-79635322) (JNJ)
- [Revlimid® (lenalidomide)](https://sec-api.dev/pdufa/lenalidomide) (JNJ)
- [Mezigdomide](https://sec-api.dev/pdufa/mezigdomide) (BMY)
- [PHE885](https://sec-api.dev/pdufa/phe885) (NVS)
- [Pomalyst (pomalidomide)](https://sec-api.dev/pdufa/pomalidomide) (BMY)
- [Ramantamig](https://sec-api.dev/pdufa/ramantamig) (JNJ)
- [Talquetamab](https://sec-api.dev/pdufa/talquetamab) (JNJ)
- [TECVAYLI (teclistamab)](https://sec-api.dev/pdufa/teclistamab) (JNJ)
- [Venclexta (venetoclax)](https://sec-api.dev/pdufa/venetoclax) (ABBV)

Calendar months: [December 2026](https://sec-api.dev/fda-calendar/2026-12)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/anitocabtagene-autoleucel.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Anitocabtagene autoleucel PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/anitocabtagene-autoleucel

```bibtex
@misc{secapidev_pdufa_anitocabtagene_autoleucel_20261116,
  title        = {Anitocabtagene autoleucel PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/anitocabtagene-autoleucel}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_anitocabtagene_autoleucel_20261116","title":"Anitocabtagene autoleucel PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/anitocabtagene-autoleucel","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
